Peter F. Kador

Content President and Chief Product Developer

Peter F. Kador received a PhD in Medicinal Chemistry from the Ohio State University and after a 25-year career at the National Institutes of Health retired as the Chief of the Laboratory of Ocular Therapeutics from the National Eye Institute. Prior to becoming Professor Emeritus, he served for 18 years as a professor at the College of Pharmacy and adjunct professor in the Departments of Ophthalmology, His work has been recognized with numerous national and international awards that include the Rhoto Cataract Research Award, Alcon Research Institute Award, Kinoshita Lectureship, Ernst H. Bárány Prize, UNMC Distinguished Scientist Award, Capital University Alumni Award, the Ohio State University College of Pharmacy Jack Beal Postbaccalaureate Alumni Achievement Award, and the Bundesverdienstkreuz (Federal Cross of Merit) from the German Government. He is a fellow of the American Association of Pharmaceutical Scientists, the Association for Research in Vision and Ophthalmology, Association of Ocular Pharmacology and Therapeutics, and an overseas fellow of the Royal Society of Medicine and a member of the American Health Council in Ophthalmology.

Dr. Kador is an expert on ocular diabetic complications and the role of aldose reductase in the development of diabetic keratopathy, cataract and retinopathy. He is also an expert on the role of oxidation and metal dyshomeostasis on vision, hearing, and neurodegeneration. He developed the topical aldose reductase inhibitor Kinostat® as well as multifunctional redox modulators (MFRMs®) for the treatment of age related degenerative diseases in the eye and neural tissues, He has also developed nutraceuticals for the treatment of ocular and diabetic complications and the use of lens cultures for assessing ocular toxicology.

Dr. Kador founded Therapeutic Vision, Inc. and is President of the National Foundation for Eye Research. as President, Trustee. Previously he was the President and Treasurer of the Association for Ocular Pharmacology and5 Therapeutics. He has organized or co-organized over 35 national and international workshops and conferences and has over 275 publications and patents.